Understanding childhood cancer development for better cures

Illustration reproduced with permission from The Red Tree by Shaun Tan, Hachette Australia, 2001.

Using multi-omics technologies, single-cell applications and innovative in vitro and in vivo models, we seek for novel druggable vulnerabilities in pediatric cancers with focus on neuroblastoma.

Research

Novel non-mutated copy number driven drug targets in neuroblastoma

Neuroblastoma is a mutational silent tumor but exhibits highly recurrent DNA copy number alterations, including large 17q gains in most high-risk cases. Our lab is using integrated bioinformatic and wet lab strategies to identify copy number affected druggable genes and further in vitro and in vivo preclinical analyses with focus on replicative stress resistors and transcriptional addiction.

SOX11, a co-opted lineage dependency factor in neuroblastoma

Our lab has identified SOX11 as a key dependency factor in neuroblastoma with a predicted role as master epigenetic regulator of the sympathetic neuronal lineage with a function distinct of the recently identified core regulatory circuitry. We study the role of SOX11 in normal sympathoblast development and how SOX11 overexpression contributes to MYCN-driven tumor formation.

News

Events

ANR 2021 (25-26-27 January 2021)

Let's get digital: 25-26-27 January 2021

Latest publications

Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions

Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions

18 December 2020

PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation

PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation

4 November 2020

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

9 July 2020

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.

30 June 2020